Registry update — unassessed
Evaluating the Safety and Efficacy of Injectable Combination Klotho and Follistatin Plasmid Gene Therapy in Humans -- An Interventional, Non-Placebo Controlled Pilot Phase Study
Trial registry update: COMPLETED. No results reported in the supplied registry record.
OBSERVATIONALMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 27, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Lack of placebo control means any reported benefits cannot be distinguished from placebo response or natural variation. The abstract does not report actual results, sample size, or effect sizes, preventing assessment of what was actually found. Pilot phase design with small uncontrolled groups cannot establish efficacy or safety for broader clinical use.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Observational
- Sample size
- —
- Duration
- —
- Population
- healthy adult volunteers
- Primary outcome
- safety and efficacy of combination klotho and follistatin gene therapy
- Effect size
- —
- Significance
- Not reported
- Journal
- Minicircle
- Published
- Aug 27, 2026
Sources
Primary source
- Minicircle ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.
An Interventional, Non-Placebo Controlled Pilot Phase Study
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.